Zipalertinib (CLN-081)

Name: Zipalertinib (CLN-081) in EGFR exon 20 insertion-mutated non-small-cell lung cancer: Disease description
Published: 2026-09-14T15:39:06-04:00

EGFR exon 20 insertion-mutated non-small-cell lung cancer

Also known as TAS6417

Manufacturer: Taiho Oncology
Regulatory submission: NDA submitted February 2026
Launch: Not announced
Last updated: September 19, 2026

Section

Product information and disease description Place of product in therapy

Disease description

12 evidence topics · 19 sources

Definition and etiology1 evidence topic · 1 source
Epidemiology1 evidence topic · 2 sources
Natural history, survival, and mortality2 evidence topics · 4 sources
Pathophysiology1 evidence topic · 1 source
Diagnosis2 evidence topics · 6 sources
Clinical presentation - signs and symptoms1 evidence topic · 2 sources
Long-term morbidity1 evidence topic · 1 source
Burden of EGFR exon 20 insertion-mutated non-small-cell lung cancer3 evidence topics · 6 sources